B
Bruno Sangro
Researcher at University of Navarra
Publications - 463
Citations - 27626
Bruno Sangro is an academic researcher from University of Navarra. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 70, co-authored 376 publications receiving 20225 citations. Previous affiliations of Bruno Sangro include Chartered Institute of Management Accountants & University of Barcelona.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae You Kim,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero +20 more
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
Journal ArticleDOI
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
Philip J. Johnson,Sarah Berhane,Chiaki Kagebayashi,Shinji Satomura,M Teng,Helen L. Reeves,James O'Beirne,Richard Fox,Anna Skowronska,D. Palmer,Winnie Yeo,Frankie Mo,Paul B.S. Lai,Mercedes Iñarrairaegui,Stephen L. Chan,Bruno Sangro,Rebecca A. Miksad,Toshifumi Tada,Takashi Kumada,Hidenori Toyoda +19 more
TL;DR: The ALBI grade offers a simple, evidence-based, objective, and discriminatory method of assessing liver function in HCC that has been extensively tested in an international setting and eliminates the need for subjective variables such as ascites and encephalopathy, a requirement in the conventional C-P grade.
Journal ArticleDOI
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Maria Reig,Zoe Mariño,Christie Perelló,Mercedes Iñarrairaegui,Andrea Ribeiro,Sabela Lens,Alba Díaz,Ramón Vilana,Anna Darnell,Maria Varela,Bruno Sangro,Jose Luis Calleja,Xavier Forns,Jordi Bruix +13 more
TL;DR: The data show an unexpected high rate and pattern of tumor recurrence coinciding with HCV clearance and, although based in a very small cohort of patients, should be taken as a note of caution and prime a large scale assessment that exceeds the individual investigators capacity.
Journal ArticleDOI
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro,Carlos Gomez-Martin,Manuel de la Mata,Mercedes Iñarrairaegui,Elena Garralda,Pilar Barrera,Jose I Riezu-Boj,Esther Larrea,Carlos Alfaro,Pablo Sarobe,Juan José Lasarte,Jose Luis Perez-Gracia,Ignacio Melero,Ignacio Melero,Jesús Prieto,Jesús Prieto +15 more
TL;DR: Tremelimumab safety profile and antitumor and antiviral activity, in patients with advanced HCC developed on HCV-induced liver cirrhosis, support further investigation.
Journal ArticleDOI
BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.
M. Reig,Alejandro Forner,Jordi Rimola,Joana Ferrer-Fàbrega,Marta Burrel,Ángeles García-Criado,Robin Katie Kelley,Peter R. Galle,Vincenzo Mazzaferro,Riad Salem,Bruno Sangro,Amit G. Singal,Arndt Vogel,Josep Fuster,C. Ayuso,Jordi Bruix +15 more
TL;DR: In this paper, the authors present those that have primed a change in the strategy and comment why some encouraging data in select interventions are still considered immature and in need to further research to gain their incorporation into an evidence-based model for clinicians and researchers.